Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.33 USD | +6.52% | +19.62% | +12.74% |
May. 02 | Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.74% | 672M | C | ||
-1.89% | 12.56B | B+ | ||
-9.59% | 7.68B | B- | ||
-1.31% | 5.29B | B | ||
+21.82% | 5.24B | C | ||
+0.02% | 4.57B | C | ||
-50.89% | 3.29B | D+ | ||
+6.42% | 2.6B | - | - | |
-10.02% | 2.2B | B- | ||
-8.29% | 1.79B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CSTL Stock
- Ratings Castle Biosciences, Inc.